Natalizumab: An antibody targeting α4-Integrin

研究成果: Article査読

1 被引用数 (Scopus)

抄録

Multiple sclerosis (MS) is a demyelinating disease of the central nervous system (CNS), in which inflammation develops upon leukocyte invasion into the CNS via the blood-brain barrier. α4-Integrin is an important cell adhesion molecule involved in the penetration process. Natalizumab is an α4-integrin-targeting monoclonal antibody that was recently approved for use as a disease-modifying therapy for MS in Japan. In this article, the mechanism of action, efficacy, and side effects of natalizumab will be reviewed.

本文言語English
ページ(範囲)1149-1158
ページ数10
ジャーナルBrain and Nerve
66
10
出版ステータスPublished - 2014 10月 1

ASJC Scopus subject areas

  • 臨床神経学

フィンガープリント

「Natalizumab: An antibody targeting α4-Integrin」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル